Review





Similar Products

blinatumomab  (MedChemExpress)
94
MedChemExpress blinatumomab
(A) The design of αP2RX5-αCD3. (B) Outline of ex vivo assays, performed in panels C, D and E, to evaluate αP2RX5-αCD3 activity. (C) Flow cytometric analysis of viable T- and Raji cell counts, 5-days after the addition of the αP2RX5-αCD3 BiTE to cultures of T cells alone or in co-culture with Raji-CD19KO cells at a 2:1 ratio. Data from P2RX5 (ΔC/ΔC, Δ10/Δ10 and FL/FL) genotyped T cells are shown, each represented by a different datapoint shape and color. Cell counts normalized to no BiTE treatment (NT) controls. (D) Target cell viability after 1-day treatment with αP2RX5-αCD3 or <t>blinatumomab</t> BiTEs at 0.01 pM concentration (Bar graphs on the left) or across a range of concentrations (Dose response curves on the right). Cell viabilities are normalized to the NT controls. Data from 2 different T-cell donors are shown and used to calculate the average EC50 value. (E) Target MM.1s cell viability, after 1-day in co-culture with T cells and the indicated concentration of αP2RX5-αCD3. The MM.1s cells were pretreated for 3-days with the indicated concentration of dexamethasone (DEX) prior to DEX washout and co-culture. Cell viabilities are normalized to the NT controls. (F) Design of αCD19-28z.αP2RX5-αCD3 construct. Transduction with this construct leads to the generation of CD19-directed CAR T cells that secrete the αP2RX5-αCD3 BiTE. (G) Outline of ex vivo assays, performed in panels H and I, to evaluate αCD19-28z.αP2RX5-αCD3 CAR T-cell activity. (H and I) Mock, αCD19-28z CAR or αCD19-28z.αP2RX5-αCD3 CAR T cells were co-cultured with the indicated cell lines at the effector CAR T cell to target Raji cell (E:T) ratio of 1:1. Viable T- and Raji cell counts were assessed via flow cytometry after 5-days of co-culture (H) . Target Raji cell viability assessed using luciferase reporter after 1-day in co-culture (I) . Cell counts and viabilities were normalized to the mock transduced T-cell control. Each bar represents data from a different T-cell donor. (J) Bioluminescent imaging of NSG mice after IV infusion with luc+ Raji CD19KO cells followed by 3×10 5 mock transduced, αP2RX5-αCD3 or αCD19-28z.αP2RX5-αCD3 CAR T cells.
Blinatumomab, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/blinatumomab/product/MedChemExpress
Average 94 stars, based on 1 article reviews
blinatumomab - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
blinatumomab (blincyto)  (Amgen)
90
Amgen blinatumomab (blincyto)
(A) The design of αP2RX5-αCD3. (B) Outline of ex vivo assays, performed in panels C, D and E, to evaluate αP2RX5-αCD3 activity. (C) Flow cytometric analysis of viable T- and Raji cell counts, 5-days after the addition of the αP2RX5-αCD3 BiTE to cultures of T cells alone or in co-culture with Raji-CD19KO cells at a 2:1 ratio. Data from P2RX5 (ΔC/ΔC, Δ10/Δ10 and FL/FL) genotyped T cells are shown, each represented by a different datapoint shape and color. Cell counts normalized to no BiTE treatment (NT) controls. (D) Target cell viability after 1-day treatment with αP2RX5-αCD3 or <t>blinatumomab</t> BiTEs at 0.01 pM concentration (Bar graphs on the left) or across a range of concentrations (Dose response curves on the right). Cell viabilities are normalized to the NT controls. Data from 2 different T-cell donors are shown and used to calculate the average EC50 value. (E) Target MM.1s cell viability, after 1-day in co-culture with T cells and the indicated concentration of αP2RX5-αCD3. The MM.1s cells were pretreated for 3-days with the indicated concentration of dexamethasone (DEX) prior to DEX washout and co-culture. Cell viabilities are normalized to the NT controls. (F) Design of αCD19-28z.αP2RX5-αCD3 construct. Transduction with this construct leads to the generation of CD19-directed CAR T cells that secrete the αP2RX5-αCD3 BiTE. (G) Outline of ex vivo assays, performed in panels H and I, to evaluate αCD19-28z.αP2RX5-αCD3 CAR T-cell activity. (H and I) Mock, αCD19-28z CAR or αCD19-28z.αP2RX5-αCD3 CAR T cells were co-cultured with the indicated cell lines at the effector CAR T cell to target Raji cell (E:T) ratio of 1:1. Viable T- and Raji cell counts were assessed via flow cytometry after 5-days of co-culture (H) . Target Raji cell viability assessed using luciferase reporter after 1-day in co-culture (I) . Cell counts and viabilities were normalized to the mock transduced T-cell control. Each bar represents data from a different T-cell donor. (J) Bioluminescent imaging of NSG mice after IV infusion with luc+ Raji CD19KO cells followed by 3×10 5 mock transduced, αP2RX5-αCD3 or αCD19-28z.αP2RX5-αCD3 CAR T cells.
Blinatumomab (Blincyto), supplied by Amgen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/blinatumomab (blincyto)/product/Amgen
Average 90 stars, based on 1 article reviews
blinatumomab (blincyto) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cd19-targeting tce blinatumomab  (Bristol Myers)
90
Bristol Myers cd19-targeting tce blinatumomab
(A) The design of αP2RX5-αCD3. (B) Outline of ex vivo assays, performed in panels C, D and E, to evaluate αP2RX5-αCD3 activity. (C) Flow cytometric analysis of viable T- and Raji cell counts, 5-days after the addition of the αP2RX5-αCD3 BiTE to cultures of T cells alone or in co-culture with Raji-CD19KO cells at a 2:1 ratio. Data from P2RX5 (ΔC/ΔC, Δ10/Δ10 and FL/FL) genotyped T cells are shown, each represented by a different datapoint shape and color. Cell counts normalized to no BiTE treatment (NT) controls. (D) Target cell viability after 1-day treatment with αP2RX5-αCD3 or <t>blinatumomab</t> BiTEs at 0.01 pM concentration (Bar graphs on the left) or across a range of concentrations (Dose response curves on the right). Cell viabilities are normalized to the NT controls. Data from 2 different T-cell donors are shown and used to calculate the average EC50 value. (E) Target MM.1s cell viability, after 1-day in co-culture with T cells and the indicated concentration of αP2RX5-αCD3. The MM.1s cells were pretreated for 3-days with the indicated concentration of dexamethasone (DEX) prior to DEX washout and co-culture. Cell viabilities are normalized to the NT controls. (F) Design of αCD19-28z.αP2RX5-αCD3 construct. Transduction with this construct leads to the generation of CD19-directed CAR T cells that secrete the αP2RX5-αCD3 BiTE. (G) Outline of ex vivo assays, performed in panels H and I, to evaluate αCD19-28z.αP2RX5-αCD3 CAR T-cell activity. (H and I) Mock, αCD19-28z CAR or αCD19-28z.αP2RX5-αCD3 CAR T cells were co-cultured with the indicated cell lines at the effector CAR T cell to target Raji cell (E:T) ratio of 1:1. Viable T- and Raji cell counts were assessed via flow cytometry after 5-days of co-culture (H) . Target Raji cell viability assessed using luciferase reporter after 1-day in co-culture (I) . Cell counts and viabilities were normalized to the mock transduced T-cell control. Each bar represents data from a different T-cell donor. (J) Bioluminescent imaging of NSG mice after IV infusion with luc+ Raji CD19KO cells followed by 3×10 5 mock transduced, αP2RX5-αCD3 or αCD19-28z.αP2RX5-αCD3 CAR T cells.
Cd19 Targeting Tce Blinatumomab, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd19-targeting tce blinatumomab/product/Bristol Myers
Average 90 stars, based on 1 article reviews
cd19-targeting tce blinatumomab - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
blinatumomab  (Bristol Myers)
90
Bristol Myers blinatumomab
(A) The design of αP2RX5-αCD3. (B) Outline of ex vivo assays, performed in panels C, D and E, to evaluate αP2RX5-αCD3 activity. (C) Flow cytometric analysis of viable T- and Raji cell counts, 5-days after the addition of the αP2RX5-αCD3 BiTE to cultures of T cells alone or in co-culture with Raji-CD19KO cells at a 2:1 ratio. Data from P2RX5 (ΔC/ΔC, Δ10/Δ10 and FL/FL) genotyped T cells are shown, each represented by a different datapoint shape and color. Cell counts normalized to no BiTE treatment (NT) controls. (D) Target cell viability after 1-day treatment with αP2RX5-αCD3 or <t>blinatumomab</t> BiTEs at 0.01 pM concentration (Bar graphs on the left) or across a range of concentrations (Dose response curves on the right). Cell viabilities are normalized to the NT controls. Data from 2 different T-cell donors are shown and used to calculate the average EC50 value. (E) Target MM.1s cell viability, after 1-day in co-culture with T cells and the indicated concentration of αP2RX5-αCD3. The MM.1s cells were pretreated for 3-days with the indicated concentration of dexamethasone (DEX) prior to DEX washout and co-culture. Cell viabilities are normalized to the NT controls. (F) Design of αCD19-28z.αP2RX5-αCD3 construct. Transduction with this construct leads to the generation of CD19-directed CAR T cells that secrete the αP2RX5-αCD3 BiTE. (G) Outline of ex vivo assays, performed in panels H and I, to evaluate αCD19-28z.αP2RX5-αCD3 CAR T-cell activity. (H and I) Mock, αCD19-28z CAR or αCD19-28z.αP2RX5-αCD3 CAR T cells were co-cultured with the indicated cell lines at the effector CAR T cell to target Raji cell (E:T) ratio of 1:1. Viable T- and Raji cell counts were assessed via flow cytometry after 5-days of co-culture (H) . Target Raji cell viability assessed using luciferase reporter after 1-day in co-culture (I) . Cell counts and viabilities were normalized to the mock transduced T-cell control. Each bar represents data from a different T-cell donor. (J) Bioluminescent imaging of NSG mice after IV infusion with luc+ Raji CD19KO cells followed by 3×10 5 mock transduced, αP2RX5-αCD3 or αCD19-28z.αP2RX5-αCD3 CAR T cells.
Blinatumomab, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/blinatumomab/product/Bristol Myers
Average 90 stars, based on 1 article reviews
blinatumomab - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
blinatumomab  (Amgen)
90
Amgen blinatumomab
(A) The design of αP2RX5-αCD3. (B) Outline of ex vivo assays, performed in panels C, D and E, to evaluate αP2RX5-αCD3 activity. (C) Flow cytometric analysis of viable T- and Raji cell counts, 5-days after the addition of the αP2RX5-αCD3 BiTE to cultures of T cells alone or in co-culture with Raji-CD19KO cells at a 2:1 ratio. Data from P2RX5 (ΔC/ΔC, Δ10/Δ10 and FL/FL) genotyped T cells are shown, each represented by a different datapoint shape and color. Cell counts normalized to no BiTE treatment (NT) controls. (D) Target cell viability after 1-day treatment with αP2RX5-αCD3 or <t>blinatumomab</t> BiTEs at 0.01 pM concentration (Bar graphs on the left) or across a range of concentrations (Dose response curves on the right). Cell viabilities are normalized to the NT controls. Data from 2 different T-cell donors are shown and used to calculate the average EC50 value. (E) Target MM.1s cell viability, after 1-day in co-culture with T cells and the indicated concentration of αP2RX5-αCD3. The MM.1s cells were pretreated for 3-days with the indicated concentration of dexamethasone (DEX) prior to DEX washout and co-culture. Cell viabilities are normalized to the NT controls. (F) Design of αCD19-28z.αP2RX5-αCD3 construct. Transduction with this construct leads to the generation of CD19-directed CAR T cells that secrete the αP2RX5-αCD3 BiTE. (G) Outline of ex vivo assays, performed in panels H and I, to evaluate αCD19-28z.αP2RX5-αCD3 CAR T-cell activity. (H and I) Mock, αCD19-28z CAR or αCD19-28z.αP2RX5-αCD3 CAR T cells were co-cultured with the indicated cell lines at the effector CAR T cell to target Raji cell (E:T) ratio of 1:1. Viable T- and Raji cell counts were assessed via flow cytometry after 5-days of co-culture (H) . Target Raji cell viability assessed using luciferase reporter after 1-day in co-culture (I) . Cell counts and viabilities were normalized to the mock transduced T-cell control. Each bar represents data from a different T-cell donor. (J) Bioluminescent imaging of NSG mice after IV infusion with luc+ Raji CD19KO cells followed by 3×10 5 mock transduced, αP2RX5-αCD3 or αCD19-28z.αP2RX5-αCD3 CAR T cells.
Blinatumomab, supplied by Amgen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/blinatumomab/product/Amgen
Average 90 stars, based on 1 article reviews
blinatumomab - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
bite (blinatumomab)  (Kimble Inc)
90
Kimble Inc bite (blinatumomab)
(A) The design of αP2RX5-αCD3. (B) Outline of ex vivo assays, performed in panels C, D and E, to evaluate αP2RX5-αCD3 activity. (C) Flow cytometric analysis of viable T- and Raji cell counts, 5-days after the addition of the αP2RX5-αCD3 BiTE to cultures of T cells alone or in co-culture with Raji-CD19KO cells at a 2:1 ratio. Data from P2RX5 (ΔC/ΔC, Δ10/Δ10 and FL/FL) genotyped T cells are shown, each represented by a different datapoint shape and color. Cell counts normalized to no BiTE treatment (NT) controls. (D) Target cell viability after 1-day treatment with αP2RX5-αCD3 or <t>blinatumomab</t> BiTEs at 0.01 pM concentration (Bar graphs on the left) or across a range of concentrations (Dose response curves on the right). Cell viabilities are normalized to the NT controls. Data from 2 different T-cell donors are shown and used to calculate the average EC50 value. (E) Target MM.1s cell viability, after 1-day in co-culture with T cells and the indicated concentration of αP2RX5-αCD3. The MM.1s cells were pretreated for 3-days with the indicated concentration of dexamethasone (DEX) prior to DEX washout and co-culture. Cell viabilities are normalized to the NT controls. (F) Design of αCD19-28z.αP2RX5-αCD3 construct. Transduction with this construct leads to the generation of CD19-directed CAR T cells that secrete the αP2RX5-αCD3 BiTE. (G) Outline of ex vivo assays, performed in panels H and I, to evaluate αCD19-28z.αP2RX5-αCD3 CAR T-cell activity. (H and I) Mock, αCD19-28z CAR or αCD19-28z.αP2RX5-αCD3 CAR T cells were co-cultured with the indicated cell lines at the effector CAR T cell to target Raji cell (E:T) ratio of 1:1. Viable T- and Raji cell counts were assessed via flow cytometry after 5-days of co-culture (H) . Target Raji cell viability assessed using luciferase reporter after 1-day in co-culture (I) . Cell counts and viabilities were normalized to the mock transduced T-cell control. Each bar represents data from a different T-cell donor. (J) Bioluminescent imaging of NSG mice after IV infusion with luc+ Raji CD19KO cells followed by 3×10 5 mock transduced, αP2RX5-αCD3 or αCD19-28z.αP2RX5-αCD3 CAR T cells.
Bite (Blinatumomab), supplied by Kimble Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bite (blinatumomab)/product/Kimble Inc
Average 90 stars, based on 1 article reviews
bite (blinatumomab) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
blinatumomab  (Informa UK Limited)
90
Informa UK Limited blinatumomab
(A) The design of αP2RX5-αCD3. (B) Outline of ex vivo assays, performed in panels C, D and E, to evaluate αP2RX5-αCD3 activity. (C) Flow cytometric analysis of viable T- and Raji cell counts, 5-days after the addition of the αP2RX5-αCD3 BiTE to cultures of T cells alone or in co-culture with Raji-CD19KO cells at a 2:1 ratio. Data from P2RX5 (ΔC/ΔC, Δ10/Δ10 and FL/FL) genotyped T cells are shown, each represented by a different datapoint shape and color. Cell counts normalized to no BiTE treatment (NT) controls. (D) Target cell viability after 1-day treatment with αP2RX5-αCD3 or <t>blinatumomab</t> BiTEs at 0.01 pM concentration (Bar graphs on the left) or across a range of concentrations (Dose response curves on the right). Cell viabilities are normalized to the NT controls. Data from 2 different T-cell donors are shown and used to calculate the average EC50 value. (E) Target MM.1s cell viability, after 1-day in co-culture with T cells and the indicated concentration of αP2RX5-αCD3. The MM.1s cells were pretreated for 3-days with the indicated concentration of dexamethasone (DEX) prior to DEX washout and co-culture. Cell viabilities are normalized to the NT controls. (F) Design of αCD19-28z.αP2RX5-αCD3 construct. Transduction with this construct leads to the generation of CD19-directed CAR T cells that secrete the αP2RX5-αCD3 BiTE. (G) Outline of ex vivo assays, performed in panels H and I, to evaluate αCD19-28z.αP2RX5-αCD3 CAR T-cell activity. (H and I) Mock, αCD19-28z CAR or αCD19-28z.αP2RX5-αCD3 CAR T cells were co-cultured with the indicated cell lines at the effector CAR T cell to target Raji cell (E:T) ratio of 1:1. Viable T- and Raji cell counts were assessed via flow cytometry after 5-days of co-culture (H) . Target Raji cell viability assessed using luciferase reporter after 1-day in co-culture (I) . Cell counts and viabilities were normalized to the mock transduced T-cell control. Each bar represents data from a different T-cell donor. (J) Bioluminescent imaging of NSG mice after IV infusion with luc+ Raji CD19KO cells followed by 3×10 5 mock transduced, αP2RX5-αCD3 or αCD19-28z.αP2RX5-αCD3 CAR T cells.
Blinatumomab, supplied by Informa UK Limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/blinatumomab/product/Informa UK Limited
Average 90 stars, based on 1 article reviews
blinatumomab - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
blinatumomab blincyto  (Amgen)
90
Amgen blinatumomab blincyto
(A) The design of αP2RX5-αCD3. (B) Outline of ex vivo assays, performed in panels C, D and E, to evaluate αP2RX5-αCD3 activity. (C) Flow cytometric analysis of viable T- and Raji cell counts, 5-days after the addition of the αP2RX5-αCD3 BiTE to cultures of T cells alone or in co-culture with Raji-CD19KO cells at a 2:1 ratio. Data from P2RX5 (ΔC/ΔC, Δ10/Δ10 and FL/FL) genotyped T cells are shown, each represented by a different datapoint shape and color. Cell counts normalized to no BiTE treatment (NT) controls. (D) Target cell viability after 1-day treatment with αP2RX5-αCD3 or <t>blinatumomab</t> BiTEs at 0.01 pM concentration (Bar graphs on the left) or across a range of concentrations (Dose response curves on the right). Cell viabilities are normalized to the NT controls. Data from 2 different T-cell donors are shown and used to calculate the average EC50 value. (E) Target MM.1s cell viability, after 1-day in co-culture with T cells and the indicated concentration of αP2RX5-αCD3. The MM.1s cells were pretreated for 3-days with the indicated concentration of dexamethasone (DEX) prior to DEX washout and co-culture. Cell viabilities are normalized to the NT controls. (F) Design of αCD19-28z.αP2RX5-αCD3 construct. Transduction with this construct leads to the generation of CD19-directed CAR T cells that secrete the αP2RX5-αCD3 BiTE. (G) Outline of ex vivo assays, performed in panels H and I, to evaluate αCD19-28z.αP2RX5-αCD3 CAR T-cell activity. (H and I) Mock, αCD19-28z CAR or αCD19-28z.αP2RX5-αCD3 CAR T cells were co-cultured with the indicated cell lines at the effector CAR T cell to target Raji cell (E:T) ratio of 1:1. Viable T- and Raji cell counts were assessed via flow cytometry after 5-days of co-culture (H) . Target Raji cell viability assessed using luciferase reporter after 1-day in co-culture (I) . Cell counts and viabilities were normalized to the mock transduced T-cell control. Each bar represents data from a different T-cell donor. (J) Bioluminescent imaging of NSG mice after IV infusion with luc+ Raji CD19KO cells followed by 3×10 5 mock transduced, αP2RX5-αCD3 or αCD19-28z.αP2RX5-αCD3 CAR T cells.
Blinatumomab Blincyto, supplied by Amgen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/blinatumomab blincyto/product/Amgen
Average 90 stars, based on 1 article reviews
blinatumomab blincyto - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


(A) The design of αP2RX5-αCD3. (B) Outline of ex vivo assays, performed in panels C, D and E, to evaluate αP2RX5-αCD3 activity. (C) Flow cytometric analysis of viable T- and Raji cell counts, 5-days after the addition of the αP2RX5-αCD3 BiTE to cultures of T cells alone or in co-culture with Raji-CD19KO cells at a 2:1 ratio. Data from P2RX5 (ΔC/ΔC, Δ10/Δ10 and FL/FL) genotyped T cells are shown, each represented by a different datapoint shape and color. Cell counts normalized to no BiTE treatment (NT) controls. (D) Target cell viability after 1-day treatment with αP2RX5-αCD3 or blinatumomab BiTEs at 0.01 pM concentration (Bar graphs on the left) or across a range of concentrations (Dose response curves on the right). Cell viabilities are normalized to the NT controls. Data from 2 different T-cell donors are shown and used to calculate the average EC50 value. (E) Target MM.1s cell viability, after 1-day in co-culture with T cells and the indicated concentration of αP2RX5-αCD3. The MM.1s cells were pretreated for 3-days with the indicated concentration of dexamethasone (DEX) prior to DEX washout and co-culture. Cell viabilities are normalized to the NT controls. (F) Design of αCD19-28z.αP2RX5-αCD3 construct. Transduction with this construct leads to the generation of CD19-directed CAR T cells that secrete the αP2RX5-αCD3 BiTE. (G) Outline of ex vivo assays, performed in panels H and I, to evaluate αCD19-28z.αP2RX5-αCD3 CAR T-cell activity. (H and I) Mock, αCD19-28z CAR or αCD19-28z.αP2RX5-αCD3 CAR T cells were co-cultured with the indicated cell lines at the effector CAR T cell to target Raji cell (E:T) ratio of 1:1. Viable T- and Raji cell counts were assessed via flow cytometry after 5-days of co-culture (H) . Target Raji cell viability assessed using luciferase reporter after 1-day in co-culture (I) . Cell counts and viabilities were normalized to the mock transduced T-cell control. Each bar represents data from a different T-cell donor. (J) Bioluminescent imaging of NSG mice after IV infusion with luc+ Raji CD19KO cells followed by 3×10 5 mock transduced, αP2RX5-αCD3 or αCD19-28z.αP2RX5-αCD3 CAR T cells.

Journal: bioRxiv

Article Title: An ancestral haplotype of P2RX5 yields a B-cell surface marker and a promising multi-lineage immunotherapy target

doi: 10.64898/2026.01.14.698748

Figure Lengend Snippet: (A) The design of αP2RX5-αCD3. (B) Outline of ex vivo assays, performed in panels C, D and E, to evaluate αP2RX5-αCD3 activity. (C) Flow cytometric analysis of viable T- and Raji cell counts, 5-days after the addition of the αP2RX5-αCD3 BiTE to cultures of T cells alone or in co-culture with Raji-CD19KO cells at a 2:1 ratio. Data from P2RX5 (ΔC/ΔC, Δ10/Δ10 and FL/FL) genotyped T cells are shown, each represented by a different datapoint shape and color. Cell counts normalized to no BiTE treatment (NT) controls. (D) Target cell viability after 1-day treatment with αP2RX5-αCD3 or blinatumomab BiTEs at 0.01 pM concentration (Bar graphs on the left) or across a range of concentrations (Dose response curves on the right). Cell viabilities are normalized to the NT controls. Data from 2 different T-cell donors are shown and used to calculate the average EC50 value. (E) Target MM.1s cell viability, after 1-day in co-culture with T cells and the indicated concentration of αP2RX5-αCD3. The MM.1s cells were pretreated for 3-days with the indicated concentration of dexamethasone (DEX) prior to DEX washout and co-culture. Cell viabilities are normalized to the NT controls. (F) Design of αCD19-28z.αP2RX5-αCD3 construct. Transduction with this construct leads to the generation of CD19-directed CAR T cells that secrete the αP2RX5-αCD3 BiTE. (G) Outline of ex vivo assays, performed in panels H and I, to evaluate αCD19-28z.αP2RX5-αCD3 CAR T-cell activity. (H and I) Mock, αCD19-28z CAR or αCD19-28z.αP2RX5-αCD3 CAR T cells were co-cultured with the indicated cell lines at the effector CAR T cell to target Raji cell (E:T) ratio of 1:1. Viable T- and Raji cell counts were assessed via flow cytometry after 5-days of co-culture (H) . Target Raji cell viability assessed using luciferase reporter after 1-day in co-culture (I) . Cell counts and viabilities were normalized to the mock transduced T-cell control. Each bar represents data from a different T-cell donor. (J) Bioluminescent imaging of NSG mice after IV infusion with luc+ Raji CD19KO cells followed by 3×10 5 mock transduced, αP2RX5-αCD3 or αCD19-28z.αP2RX5-αCD3 CAR T cells.

Article Snippet: The size and concentration of the αP2RX5-αCD3 BiTE was assessed via western blotting with an anti-His-Tag antibody (Cell Signaling Technology, D3I1O clone) and a standard curve generated from Blinatumomab (MedChem Express, HY-P9963).

Techniques: Ex Vivo, Activity Assay, Co-Culture Assay, Concentration Assay, Construct, Transduction, Cell Culture, Flow Cytometry, Luciferase, Control, Imaging